Patterns of incident genital human papillomavirus infection in women: A literature review and meta-analysis
暂无分享,去创建一个
[1] H. Zou,et al. Positivity and incidence of human papillomavirus in women attending gynecological department of a major comprehensive hospital in Kunming, China 2012–2014 , 2016, Journal of medical virology.
[2] A. Chatterjee. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon , 2014, Expert review of vaccines.
[3] J. Berkhof,et al. Prospective follow‐up of 2,065 young unscreened women to study human papillomavirus incidence and clearance , 2013, International journal of cancer.
[4] Joelle M. Brown,et al. High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects , 2013, Sexually Transmitted Infections.
[5] A. Burke,et al. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. , 2012, Cancer research.
[6] S. Hibbitts. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial , 2012, Journal of Family Planning and Reproductive Health Care.
[7] P. Gravitt. The known unknowns of HPV natural history. , 2011, The Journal of clinical investigation.
[8] S. Grénman,et al. Incident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study , 2011, BMC infectious diseases.
[9] H. Trottier,et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. , 2010, Cancer research.
[10] N. Surico,et al. Role of HPV testing in the follow-up of women treated for cervical dysplasia , 2010, Archives of Gynecology and Obstetrics.
[11] C. Wheeler,et al. Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[12] E. Weiderpass,et al. Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda , 2010, Infectious Agents and Cancer.
[13] Diane Solomon,et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. , 2010, Journal of the National Cancer Institute.
[14] X. Castellsagué,et al. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. , 2009, Gynecologic oncology.
[15] A. Saah,et al. Prevalence and Incidence of HPV Genital Infection in Women , 2009, Sexually transmitted diseases.
[16] S. Kjaer,et al. Acquisition of High-Risk Human Papillomavirus Infection in a Population-Based Cohort of Danish Women , 2009, Sexually transmitted diseases.
[17] N. Muñoz,et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial , 2009, The Lancet.
[18] M. I. Rosa,et al. Persistence and clearance of human papillomavirus infection: a prospective cohort study. , 2008, American journal of obstetrics and gynecology.
[19] Yurii B. Shvetsov,et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. , 2008, Cancer research.
[20] Jennifer S. Smith,et al. Age-specific prevalence of infection with human papillomavirus in females: a global review. , 2008, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[21] N. Kiviat,et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. , 2008, The Journal of infectious diseases.
[22] F. Buonaguro,et al. Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. , 2008, The Journal of general virology.
[23] S. Gange,et al. Determinants of Incidence and Clearance of High-Risk Human Papillomavirus Infections in Rural Rakai, Uganda , 2008, Cancer Epidemiology Biomarkers & Prevention.
[24] H. Trottier,et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. , 2008, The Journal of infectious diseases.
[25] S. Franceschi,et al. Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study , 2008, BMC infectious diseases.
[26] E. Dasbach,et al. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women , 2007, Infectious Agents and Cancer.
[27] N. Muñoz,et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. , 2007, The Lancet. Infectious diseases.
[28] S. Wacholder,et al. The Natural History of Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia Among Young Women in the Guanacaste Cohort Shortly After Initiation of Sexual Life , 2007, Sexually transmitted diseases.
[29] E. Dasbach,et al. Incidence and Duration of Cervical Human Papillomavirus 6, 11, 16, and 18 Infections in Young Women: An Evaluation from Multiple Analytic Perspectives , 2007, Cancer Epidemiology Biomarkers & Prevention.
[30] G. Krogh,et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.
[31] Xavier Castellsagué,et al. Chapter 1: HPV in the etiology of human cancer. , 2006, Vaccine.
[32] L. Parker,et al. Human papillomavirus infection and cervical intraepithelial neoplasia in a cohort of low-risk women. , 2006, European journal of obstetrics, gynecology, and reproductive biology.
[33] D. Tate,et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study , 2006, BMJ : British Medical Journal.
[34] C. Wheeler,et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.
[35] V. Moreno,et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. , 2005, The Journal of infectious diseases.
[36] S. Wacholder,et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.
[37] A. Muñoz,et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. , 2004, The Journal of infectious diseases.
[38] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[39] C. Wheeler,et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. , 2004, Vaccine.
[40] M. J. Whitley,et al. Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring , 2004, Journal of medical virology.
[41] S. Syrjänen,et al. Acquisition of High-Risk Human Papillomavirus Infections and Pap Smear Abnormalities among Women in the New Independent States of the Former Soviet Union , 2004, Journal of Clinical Microbiology.
[42] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[43] M. Abrahamowicz,et al. Occurrence of Cervical Infection with Multiple Human Papillomavirus Types is Associated with Age and Cytologic Abnormalities , 2003, Sexually transmitted diseases.
[44] Michal Abrahamowicz,et al. The natural history of type-specific human papillomavirus infections in female university students. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[45] J. Kaczorowski,et al. Incidence, clearance and predictors of human papillomavirus infection in women. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[46] C. Woodman,et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia , 2003, The Lancet.
[47] C. Wheeler,et al. A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.
[48] R. Burk,et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. , 2002, The Journal of infectious diseases.
[49] A. Giuliano,et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. , 2002, The Journal of infectious diseases.
[50] R. Greenblatt,et al. The Impact of HIV Infection and Immunodeficiency on Human Papillomavirus Type 6 or 11 Infection and on Genital Warts , 2002, Sexually transmitted diseases.
[51] N. Kiviat,et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[52] L. Young,et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship , 2002, BJOG : an international journal of obstetrics and gynaecology.
[53] T. Rohan,et al. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. , 2001, The Journal of infectious diseases.
[54] L. Ahdieh,et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. , 2001, The Journal of infectious diseases.
[55] A. Moscicki,et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. , 2001, JAMA.
[56] N. Kiviat,et al. Concurrent and sequential acquisition of different genital human papillomavirus types. , 2000, The Journal of infectious diseases.
[57] T. Rohan,et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. , 1999, The Journal of infectious diseases.
[58] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[59] K. Shah,et al. Detection of Genital Human Papillomavirus and Associated Cytological Abnormalities Among College Women , 1998, Sexually transmitted diseases.
[60] S. Thompson,et al. Detecting and describing heterogeneity in meta-analysis. , 1998, Statistics in medicine.
[61] R. Burk,et al. Natural history of cervicovaginal papillomavirus infection in young women , 1998 .
[62] M. Chiasson,et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. , 1997, The New England journal of medicine.
[63] J. Kónya,et al. Follow-up of human papillomavirus (HPV) DNA and local anti-HPV antibodies in cytologically normal pregnant women Received: 17 July 1996 , 1996, Medical Microbiology and Immunology.
[64] M. Evander,et al. Human Papillomavirus Infection Is Transient in Young Women: A PopulationBased Cohort Study , 1995 .
[65] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .
[66] H. Kitchener,et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.
[67] R. Pandey,et al. Type-specific incidence and persistence of HPV infection among young women: a prospective study in North India. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[68] Chee-Jen Chang,et al. Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology—A population‐based cohort study from Taiwan , 2010, International journal of cancer.
[69] J. T. Cox,et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors , 2007, CA: a cancer journal for clinicians.
[70] David R. Scott,et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. , 2001, The Journal of infectious diseases.
[71] M. Evander,et al. Human papillomavirus infection is transient in young women: a population-based cohort study. , 1995, The Journal of infectious diseases.